| abstract |
The present invention relates to methods and compositions related to T cells redirected to CD70 for immunotherapy of CD70-positive malignancies. In an aspect of the invention, CD70-specific T cells are used. In a particular aspect, there are T cells expressing new molecules comprising the full length CD70 receptor (CD27) fused to the zeta signaling domain of the T-cell receptor complex. These T cells reorganize CD70-positive tumor cells and have cytolytic activity against CD70-positive cancer cells. |